The White House has dropped the nomination of Dr. Heidi Overton, President Trump’s pick for Food and Drug Administration commissioner, according to a senior administration official and other people familiar with the decision.
The Senate health committee had been scheduled to vote on Overton’s nomination Wednesday.
Axios was first to report that Overton was dropped.
Mr. Trump nominated Overton — a physician and White House domestic policy staffer — to the FDA role over the summer. The agency, which regulates products that account for about 20% of U.S. consumer spending, has not had a Senate-confirmed leader since Dr. Marty Makary was forced out in May.
Overton had struggled to shore up support among Senate Republicans, CBS News had previously reported. Some lawmakers and administration allies had expressed skepticism of Overton, partly due to her testimony regarding the FDA-approved abortion drug mifepristone and her execution of Mr. Trump’s pro-vape policies.
Republican Sen. Bill Cassidy of Louisiana, the outgoing chair of the Senate Health, Education, Labor and Pensions Committee, told CBS News late Tuesday he saw a possible pathway for Overton to advance out of his committee. The issue was still being discussed by members, and the committee had not informed the White House that it lacked the votes.
Two sources familiar with the matter said the White House shared its decision to withdraw Overton’s nomination Tuesday evening. At the time, whip efforts were still underway to garner enough Republican votes to advance Overton.
Prior to the decision, the White House had begun talking to other potential candidates for FDA chief, including some who could serve in an acting capacity and thus forgo Senate confirmation, a source told CBS News earlier Tuesday. The agency is currently run by acting Commissioner Kyle Diamantas.
Two sources indicated Sen. Roger Marshall of Kansas, a doctor, is making a play for the FDA post. He lost his reelection bid to Democrat Adam Hamilton earlier this month.
Any Senate-confirmed FDA commissioner would likely need to be confirmed during a narrow window before Democrats take control of the chamber in January.
CBS News’ “Face the Nation with Margaret Brennan” asked Cassidy on Sunday whether Republicans would seek to put a permanent FDA commissioner in place. He said, “we’re not going to have perfection.”
“The question is, do we want a series of short-term administrators who probably will have more influence from the secretary, as opposed to someone who may be not, you know, the perfect candidate in somebody’s mind, but at least would be a permanent one and have the ability to establish some independence?” he said.

